Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
Biogen’s aducanumab filing is keenly awaited, as are clinical data from Sanofi, Bristol Myers Squibb, Lilly and others.
As Merck & Co’s Keynote-361 study fails, attention turns to Bavencio’s Asco late-breaker and the potential of Padcev.
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.
Roche secures a front-line liver cancer label, but rival data at Asco show that the competition isn’t resting on its laurels.
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
In anti-BCMA therapy Johnson & Johnson looks to have upstaged Bristol Myers Squibb again, and both companies have backups.